Our discoveries that circulating ACE2+ EVs are upregulated in the blood from COVID-19 patients and that the engineered ACE2+ EVs block SARS-CoV-2 infection implies that evACE2 presents with a potential innate antiviral mechanism. Here, ACE2 is linked to COVID-19.